NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva's portfolio of breast aesthetics and reconstruction.
Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 3,575 shares of the stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $60.08, for a total value of $214,786.00. Following the completion of the transaction, the director owned 1,220,004
Establishment Labs (NASDAQ: ESTA - Get Free Report) and HealthEquity (NASDAQ: HQY - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Valuation and Earnings This table compares Establishment Labs and
Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a
Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection security software, delivered disappointing earnings results and an outlook below expectations.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.98 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, a.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra “Sandra” Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. “Over the past.
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Pediatrix Medical Group (NYSE: MD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Profitability This table compares Establishment Labs and
